The MADIT S-ICD trial is designed to evaluate if subjects with a prior myocardial infarction, diabetes mellitus and a relatively preserved ejection fraction of 36-50% will have a survival benefit from receiving a subcutaneous implantable cardioverter defibrillator (S-ICD) when compared to those receiving conventional medical therapy.
Press Releases
January 26, 2022
Boston magazine has released its annual listing of Boston’s Top Doctors and this year’s recognition includes 12 members of the MelroseWakefield Healthcare medical staff among the area’s most respected experts.